Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$970M |
| 2 |
AbbVie
ABBV
|
+$554M |
| 3 |
IBM
IBM
|
+$535M |
| 4 |
TC Energy
TRP
|
+$489M |
| 5 |
McKesson
MCK
|
+$459M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.32B |
| 2 |
MON
Monsanto Co
MON
|
+$1.1B |
| 3 |
Kinder Morgan
KMI
|
+$684M |
| 4 |
Amgen
AMGN
|
+$670M |
| 5 |
Danaher
DHR
|
+$664M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.92% |
| 2 | Technology | 12.36% |
| 3 | Communication Services | 10.31% |
| 4 | Consumer Discretionary | 10.04% |
| 5 | Energy | 10% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$222B
| $13.2B | 4.35% |
78,911,687
-3,963,776
| -5% | -$670M |
|
|
2
AbbVie
ABBV
$435B
| $10.2B | 3.36% |
161,275,127
+8,556,414
| +6% | +$554M |
|
3
Amazon
AMZN
$2.96T
| $8.97B | 2.96% |
214,158,420
-3,972,360
| -2% | -$152M |
|
4
Philip Morris
PM
$295B
| $7.96B | 2.63% |
81,832,782
-1,197,920
| -1% | -$120M |
|
5
Verizon
VZ
$196B
| $7.82B | 2.58% |
150,363,577
-5,352,629
| -3% | -$287M |
|
6
Oracle
ORCL
$423B
| $6.32B | 2.09% |
160,931,388
-2,192,977
| -1% | -$89.4M |
|
7
Texas Instruments
TXN
$261B
| $5.3B | 1.75% |
75,495,038
-7,776,858
| -9% | -$530M |
|
8
Netflix
NFLX
$309B
| $5.1B | 1.69% |
517,453,760
+17,775,740
| +4% | +$170M |
|
9
Union Pacific
UNP
$174B
| $4.82B | 1.59% |
49,440,865
-3,884,174
| -7% | -$363M |
|
10
Altria Group
MO
$114B
| $4.54B | 1.5% |
71,845,669
-3,795,048
| -5% | -$252M |
|
11
Canadian Natural Resources
CNQ
$93.8B
| $4.21B | 1.39% |
269,090,372
+893,404
| +0.3% | +$13.6M |
|
12
EOG Resources
EOG
$70.7B
| $4.18B | 1.38% |
43,174,411
+23,331
| +0.1% | +$2.05M |
|
13
American International
AIG
$41.3B
| $4.15B | 1.37% |
69,980,655
+270,600
| +0.4% | +$15.5M |
|
14
Alibaba
BABA
$308B
| $4.1B | 1.36% |
38,759,360
+2,637,869
| +7% | +$244M |
|
15
UnitedHealth
UNH
$370B
| $4.08B | 1.35% |
29,117,382
-1,206
| -0% | -$169K |
|
16
Intel
INTC
$513B
| $4.06B | 1.34% |
107,606,956
+4,502,584
| +4% | +$159M |
|
17
Stryker
SYK
$130B
| $3.9B | 1.29% |
33,537,131
+556,349
| +2% | +$64.8M |
|
18
Accenture
ACN
$108B
| $3.47B | 1.15% |
28,388,103
-127,162
| -0.4% | -$14.5M |
|
19
Alphabet (Google) Class C
GOOG
$4.32T
| $3.43B | 1.14% |
88,366,360
+3,559,480
| +4% | +$135M |
|
20
Coca-Cola
KO
$375B
| $3.35B | 1.11% |
79,077,450
-3,291
| -0% | -$144K |
|
21
Medtronic
MDT
$112B
| $3.28B | 1.08% |
37,968,014
+462,891
| +1% | +$40.3M |
|
22
AT&T
T
$163B
| $3.15B | 1.04% |
102,544,830
-7,602,633
| -7% | -$240M |
|
23
Boeing
BA
$185B
| $2.71B | 0.9% |
20,586,605
+857,985
| +4% | +$113M |
|
|
24
Alphabet (Google) Class A
GOOGL
$4.33T
| $2.71B | 0.9% |
67,372,420
+4,805,940
| +8% | +$188M |
|
25
Halliburton
HAL
$26.6B
| $2.7B | 0.89% |
60,102,325
+2,639,382
| +5% | +$115M |
|
Similar funds
Capital Research Global Investors's Q3 2016 Portfolio in Review
As of Q3 2016, Capital Research Global Investors held 443 positions worth $303B, up 3.4% from $292B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Capital Research Global Investors's Q3 2016 filing shows 24 new, 126 increased, 140 reduced and 30 closed positions. Its largest new stake was TC Energy: 10,475,000 shares worth $498M. The largest sale was Alexion Pharmaceuticals, an estimated $1.32B.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 19% a quarter earlier, followed by Technology and Communication Services.
- Capital Research Global Investors's largest Q3 2016 buy was TC Energy: 10,475,000 shares worth $498M.
- Capital Research Global Investors added most to ExxonMobil in Q3 2016, an estimated $970M increase.
- Capital Research Global Investors's biggest Q3 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.32B.
- Capital Research Global Investors fully exited Waste Management in Q3 2016, selling an estimated $637M.
- Capital Research Global Investors's ten largest holdings make up 25% of its $303B portfolio in Q3 2016.
- Capital Research Global Investors opened 24 new positions and closed 30 in Q3 2016.
- Capital Research Global Investors's portfolio value rose 3.4% quarter-over-quarter to $303B.
Based on Capital Research Global Investors's 13F filing for Q3 2016, filed 14 Nov 2016.